Natera seeks FDA approval for bladder cancer test after trial success
Natera (NASDAQ:NTRA) submitted a formal application for U.S. regulatory approval of its Signatera molecular residual disease test as a companion diagnostic for bladder cancer, moving to solidify its lead in the burgeoning field of precision oncology.





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)




-640x400.jpg&w=1200&q=75)









